An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States Who Are Currently Benefiting or Have Benefited from Gefitinib Treatment

Trial Profile

An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States Who Are Currently Benefiting or Have Benefited from Gefitinib Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Dec 2017 to 29 Dec 2017.
    • 24 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 29 Dec 2017.
    • 24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top